Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology Annual Meeting
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® for Follicular Lymphoma in Argentina and Mexico
Incyte Announces the European Commission Approval of Zynyz® for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal
Incyte Announces Positive CHMP Opinion for Zynyz® for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab as a First-line Treatment for Diffuse Large B-Cell Lymphoma
Incyte Japan Announces Approval of Minjuvi® in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
Incyte Announces European Commission Approval of Minjuvi® for the Treatment of Relapsed or Refractory Follicular Lymphoma
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia
Incyte's First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
EnerCom Announces Initial List of Presenting Companies for the 31st Annual Energy Investment Conference to be held August 17-19, 2026, in Denver, Colorado
